Evidence map›Paper›PMID 38376260›Full record

ArticlemBio2024

Activin A levels are raised during human tuberculosis and blockade of the activin signaling axis influences murine responses to

Natalie E Nieuwenhuizen, Geraldine Nouailles, Jayne S Sutherland, Joanna Zyla, Arja H Pasternack, Jan Heyckendorf, Björn C Frye, Kerstin Höhne, Ulrike Zedler, Silke Bandermann and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 10 institutions in 5 countries.

Natalie E NieuwenhuizenDepartment of Immunology, Max Planck Institute for Infection Biology, Chariteplatz, Berlin, Germany.ORCID 0000-0001-5749-2462
Geraldine NouaillesDepartment of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Jayne S SutherlandVaccines and Immunity Theme, Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, The Gambia.
Joanna ZylaDepartment of Data Science and Engineering, Silesian University of Technology, Gliwice, Poland.
Arja H PasternackDepartment of Physiology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Jan HeyckendorfDepartment of Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany.
Björn C FryeDepartment of Pneumology, Clinic, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Kerstin HöhneDepartment of Pneumology, Clinic, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Ulrike ZedlerDepartment of Immunology, Max Planck Institute for Infection Biology, Chariteplatz, Berlin, Germany.
Silke BandermannDepartment of Immunology, Max Planck Institute for Infection Biology, Chariteplatz, Berlin, Germany.
Ulrike Abu AbedMicroscopy Core Facility, Max Planck Institute for Infection Biology, Chariteplatz, Berlin, Germany.
Volker BrinkmannMicroscopy Core Facility, Max Planck Institute for Infection Biology, Chariteplatz, Berlin, Germany.
Birgitt GutbierDepartment of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Martin WitzenrathDepartment of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Norbert SuttorpDepartment of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Gernot ZisselDepartment of Pneumology, Clinic, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Christoph LangeDivision of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.
Olli RitvosDepartment of Physiology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Stefan H E KaufmannDepartment of Immunology, Max Planck Institute for Infection Biology, Chariteplatz, Berlin, Germany.
CAPNETZ Study group
DZIF TB study group
Humboldt-Universität zu Berlin · DEMax Planck Institute for Infection Biology · DEUniversity of Freiburg · DEUniversity of Helsinki · FIBaylor College of Medicine · USInstitute for Advanced Study · USMRC Unit the Gambia · GMSilesian University of Technology · PLUniversity Hospital Schleswig-Holstein · DEUniversity of Würzburg · DE

Funding

Medical Research Council MC_U190071468Medical Research Council MC_UU_00031/6
6 · The paper itself

Abstract

Activin A strongly influences immune responses; yet, few studies have examined its role in infectious diseases. We measured serum activin A levels in two independent tuberculosis (TB) patient cohorts and in patients with pneumonia and sarcoidosis. Serum activin A levels were increased in TB patients compared to healthy controls, including those with positive tuberculin skin tests, and paralleled severity of disease, assessed by X-ray scores. In pneumonia patients, serum activin A levels were also raised, but in sarcoidosis patients, levels were lower. To determine whether blockade of the activin A signaling axis could play a functional role in TB, we harnessed a soluble activin type IIB receptor fused to human IgG1 Fc, ActRIIB-Fc, as a ligand trap in a murine TB model. The administration of ActRIIB-Fc to IMPORTANCE: Tuberculosis remains the leading cause of death by a bacterial pathogen. The etiologic agent of tuberculosis,

Indexed as

Mycobacterium tuberculosisPneumoniaSarcoidosisTuberculosisActivinsAnimalsBiomarkersHumansImmunoglobulin GLigandsMiceTuberculinactivin AActivinsBiomarkersImmunoglobulin GLigandsTuberculinactivin AActRIIBCD103IP-10latent TB infectionpneumoniaresident memory T cellssarcoidosistreatment monitoringTRMtuberculosis

Identifiers

PMID38376260
PMCPMC10936190
OpenAlexW4391954908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.